SGLT2 Inhibitors Drugs: Names, Uses, And Safety Notes

Key Takeaways

• They lower glucose by increasing urinary sugar loss.
• Common options include dapagliflozin, empagliflozin, canagliflozin, and ertugliflozin.
• Some products combine an SGLT2 inhibitor with metformin.
• Risks include dehydration and certain genital or urinary infections.

Overview

If you manage type 2 diabetes, you may see an SGLT2 inhibitor mentioned. Learning the basics of sglt2 inhibitors drugs helps you read labels, compare options, and ask better questions. This class is also discussed in heart and kidney care, depending on the product label. The details matter because benefits and risks are not identical across brands.

SGLT2 inhibitors are also called sodium glucose cotransporter 2 inhibitors (kidney “glucose re-absorber” blockers). In plain terms, they help your kidneys pass more glucose into urine. That mechanism affects blood sugar, fluid balance, and sometimes blood pressure. Your clinician will weigh that against your kidney function, other medicines, and infection history.

You will see both generic names and brand names in this space. For example, dapagliflozin is found as Farxiga, while the empagliflozin brand name is Jardiance. Canagliflozin brand name is Invokana. Combination tablets also exist, such as Invokamet (canagliflozin with metformin), along with other combinations like Synjardy and Xigduo.

Why it matters: The same class can look similar, yet differ in labeled uses and precautions.

We operate as a prescription referral platform, not a prescriber’s office.

For orientation, you can browse an overview of options in the SGLT2 Inhibitors Category. If you want deeper context on how this class shows up in cardiology, see Heart Failure Care Changes. The goal is clarity, not self-treatment. Any medication choice should stay between you and your prescriber.

SGLT2 Inhibitors Drugs: How This Class Works

SGLT2 is a transporter in the kidney that normally reclaims glucose from urine back into the bloodstream. Blocking that transporter leads to more glucose being excreted. Clinically, you may hear this described as increased “glucosuria” (glucose in urine). In everyday language, it means you pee out some sugar that would otherwise stay in circulation.

This kidney-based action can also increase urine volume, especially early on. Some people notice more frequent urination or thirst. Because fluid shifts can occur, clinicians often review blood pressure medicines and diuretics (“water pills”). Kidney function tests may also guide whether a specific product can be started or continued.

The mechanism can also explain a few practical issues. Urine containing more glucose can raise the likelihood of genital yeast infections in some people. It may also change how you should plan for illness, fasting, or surgery. Those topics are best handled with individualized guidance from your care team.

Core Concepts

This class is sometimes talked about as “sglt inhibitors,” but the standard term is SGLT2 inhibitors. You may also see the broader phrase sodium glucose cotransporter 2 inhibitors in clinical articles. While these medicines share a core mechanism, they are not interchangeable for every person or every labeled use.

It also helps to separate three ideas: the drug class, the generic ingredient, and the brand product. For example, Farxiga is a brand, and dapagliflozin is the generic ingredient inside it. Jardiance class of medication is an SGLT2 inhibitor, while Jardiance itself is the brand for empagliflozin. That naming structure matters when you compare labels, refills, and combination tablets.

What “indications” really mean on a label

You will often hear “indications,” which are the approved uses listed in product labeling. In plain language, indications describe what a regulator has cleared a product to be used for. That differs from “class effects,” which are trends seen across related medicines. A prescriber may consider both, but the label is the most concrete reference for what a given brand is approved to treat.

For this class, labels commonly include type 2 diabetes management. Some products also have labeled roles in certain heart failure or chronic kidney disease settings. Those details vary by product and by country, and they can change as labels are updated. When you read summaries online, double-check them against the current prescribing information.

SGLT2 inhibitors list: generics, brands, and combinations

Below is a practical sglt2 inhibitors list to help you map names to brands. It is not a complete global list, and it does not replace the official label. Think of it as a translation tool when you see a new name in your chart.

If you are reviewing specific product pages, keep the ingredient in mind. For example, Farxiga Dapagliflozin and Jardiance are different brands with different labels. For canagliflozin, you may see Invokana. For combination therapy, Invokamet is one example that pairs an SGLT2 inhibitor with metformin.

Uses you may see: diabetes, heart, and kidney contexts

In everyday searches, people look up farxiga uses, invokana used for, and empagliflozin uses. The short answer is that these medicines are most commonly used in type 2 diabetes care, and some also have approvals in heart failure or chronic kidney disease settings. The exact wording matters, because “heart failure” is not one single condition, and “kidney disease” spans a wide range of severity.

When someone says “Farxiga for diabetes,” they are usually referring to glucose control in type 2 diabetes as part of a broader plan. “Farxiga for heart failure” and “Jardiance heart failure” appear in patient discussions because certain products in this class have been studied and approved for specific heart failure indications. You can read more detail in What Farxiga Is Used For and Jardiance Drug Class.

What people notice day to day (and what not to expect)

Because the mechanism increases glucose loss in urine, some people see modest weight changes. This is why “farxiga weight loss” shows up in searches. Still, these medicines are not approved as weight-loss drugs. Any weight change can be influenced by diet, fluid shifts, and other medications.

You may also hear the term empagliflozin drug classification. Clinically, it is an SGLT2 inhibitor used in type 2 diabetes, and in some settings for cardiovascular or kidney outcomes as labeled. In plain terms, it is not insulin, and it does not replace insulin when insulin is needed. People with type 1 diabetes should rely on their prescriber’s direction, since risks like ketoacidosis may differ.

Side effects and safety signals to discuss

When people search empagliflozin side effects, they usually want practical expectations. Common issues can include genital yeast infections, urinary tract infections, and increased urination. Some people can develop low blood pressure symptoms, such as dizziness, especially if they are also on diuretics or have low fluid intake. Kidney lab changes can occur, which is why clinicians monitor renal function over time.

More serious but less common risks are also discussed in official labeling. These can include diabetic ketoacidosis (a dangerous acid build-up), even when glucose is not extremely high. Severe genital or perineal infections have been reported rarely. Because risks vary by person, clinicians often ask about prior infections, dehydration, alcohol intake patterns, and planned surgery or prolonged fasting.

When required, we verify prescription information with your prescriber before dispensing proceeds.

Bring specifics to your next visit. Ask what symptoms should trigger a call to the clinic. Also ask how your other medicines interact with fluid balance. This is especially relevant if you take blood pressure drugs, diuretics, or NSAIDs (nonsteroidal anti-inflammatory drugs, common pain relievers). Getting these details clear up front can prevent avoidable side effects.

Practical Guidance

Start with a simple inventory. List all current medications, including over-the-counter pain relievers and supplements. Note any history of recurrent yeast infections or UTIs, and any episodes of fainting or dehydration. Those details help your clinician decide whether this class fits your risk profile.

If you are already taking sglt2 inhibitors drugs, prepare a short set of “monitoring questions” for your next appointment. Ask how often kidney labs are typically checked for someone with your health history. Also ask what to do if you cannot keep fluids down due to gastroenteritis (“stomach flu”). You are not asking for a dose change; you are asking for a plan.

Quick tip: Keep a dated list of side effects and sick days.

Use this checklist to structure a clinic conversation:

• Medication purpose: match to labeled indication
• Kidney status: review recent lab trends
• Fluid balance: diuretics and low blood pressure
• Infection risk: genital yeast and UTIs
• Procedure planning: surgery, fasting, imaging prep
• Red flags: when to seek urgent evaluation

If you are comparing combination pills, confirm the second ingredient. For example, Invokamet includes metformin along with canagliflozin. That matters if you have had prior metformin side effects or if your clinician is monitoring certain lab values tied to metformin use. Also confirm whether the product is an immediate-release or extended-release formulation, because that affects how it is taken.

Dispensing is completed by licensed Canadian pharmacies, with cash-pay access that may help people without insurance.

Compare & Related Topics

Many people compare sglt2 inhibitors drugs with other oral diabetes classes. DPP-4 inhibitors work differently, acting through incretin pathways that affect insulin and glucagon signaling. They do not cause glucosuria, so their side effect profile looks different. If you want to browse alternatives by class, see the DPP-4 Inhibitors Category for a hub-style view.

It is also common to compare within the SGLT2 class itself, especially between Invokana and Jardiance. That comparison should stay grounded in each product’s approved indications, your kidney function, and your broader medication plan. For a structured overview, see Invokana Vs Jardiance. If heart failure is part of your medical history, use disease-specific sources as well, since “heart failure” can mean different phenotypes and treatment priorities.

Authoritative Sources

Because labels evolve, a reliable way to fact-check sglt2 inhibitors drugs is to read the latest prescribing information and regulator summaries. When an article makes a claim about indications or risks, look for whether it is stated in official labeling. Your pharmacist and prescriber can help interpret how that language applies to your situation.

Here are a few reputable starting points:

• FDA Drug Approvals and Databases overview
• FDA Drug Safety communications
• American Diabetes Association clinical resources

For more site-specific reading, you can also review Farxiga Side Effects to see how common issues are typically described. Use these references as context, then confirm decisions with your clinician.

Recap

SGLT2 inhibitors can play a meaningful role in modern type 2 diabetes care. They are distinct because they act through the kidney rather than the pancreas. That difference affects both their potential benefits and their risk profile.

If sglt2 inhibitors drugs are on your medication list, focus on three basics: the exact ingredient, the labeled indication, and the safety plan for illness or dehydration. Bring your questions to a pharmacist or prescriber who can align the label with your medical history. Further reading from official sources can help you stay current as guidance evolves.

This content is for informational purposes only and is not a substitute for professional medical advice.

________________________________________________________________________________________

Medically Reviewed by: Ma Lalaine Cheng.,MD.,MPH